Kodiak is dedicated to researching and commercializing innovative treatments for high prevalence retinal diseases. Their ABC Platform™ combines antibody-based and chemistry-based therapies to design and manufacture next generation retinal medicines. Their lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for retinal vascular diseases. Kodiak also has a pipeline of product candidates, including KSI-501, a dual inhibitor antibody biopolymer conjugate targeting VEGF and IL-6. They are expanding their research pipeline to include triplet inhibitors for multifactorial retinal diseases. Located in Palo Alto, Kodiak fosters a culture of curiosity, creativity, and compassion, and offers a vibrant work-life balance.